{"product_id":"cancer-monoclonal-antibodies-market-global-industry-trends-share-size-growth-opportunity-and-forecast-2023-2028","title":"Cancer Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028","description":"\u003cp\u003eCancer Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028\u003cbr\u003e\nThe global cancer monoclonal antibodies market size reached US$ 44.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 56.7 Billion by 2028, exhibiting a growth rate (CAGR) of 4.1% during 2023-2028.\u003c\/p\u003e \n\n\u003cp\u003eA cancer monoclonal antibody refers to a laboratory-generated molecule that is engineered to mimic the immune system’s attack on cancer cells. It can bind to antigens present on the surface of cancer cells and flag them to trigger the destruction of cell membranes, block cell growth and immune system inhibitors. It can also deliver treatment radiations directly to the cancer cells to neutralize or destroy them. Some of the most commonly used monoclonal antibodies include murine, chimeric and humanized antibodies that are employed in the treatment of cancer in the blood, liver, brain and breast.\u003c\/p\u003e\n\n\u003cp\u003eThe increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient’s body and can also be used for the treatment of autoimmune and inflammatory diseases. Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth. With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug. They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe. Other factors, including rising preference for personalized medicines, extensive research and development (R\u0026amp;D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further.\u003c\/p\u003e \n\n\u003cp\u003eKey Market Segmentation:\u003cbr\u003e\nIMARC Group provides an analysis of the key trends in each sub-segment of the global cancer monoclonal antibodies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on antibody type, medication type, end-user and application.\u003c\/p\u003e\n\n\u003cp\u003eBreakup by Antibody Type:\u003c\/p\u003e\n\n\u003cp\u003eMurine Antibodies\u003cbr\u003e\nChimeric Antibodies\u003cbr\u003e\nHumanized Antibodies\u003cbr\u003e\nOthers\u003cbr\u003e\n \u003cbr\u003e\nBreakup by Medication Type:\u003c\/p\u003e\n\n\u003cp\u003eBevacizumab (Avastin)\u003cbr\u003e\nRituximab (Rituxan)\u003cbr\u003e\nTrastuzumab (Herceptin)\u003cbr\u003e\nCetuximab (Erbitux)\u003cbr\u003e\nPanitumumab (Vectibix)\u003cbr\u003e\nOthers\u003cbr\u003e\n \u003cbr\u003e\nBreakup by Application:\u003c\/p\u003e\n\n\u003cp\u003eBreast Cancer\u003cbr\u003e\nBlood Cancer\u003cbr\u003e\nLiver Cancer\u003cbr\u003e\nBrain Cancer\u003cbr\u003e\nColorectal Cancer\u003cbr\u003e\nOthers\u003cbr\u003e\n \u003cbr\u003e\nBreakup by End-User:\u003c\/p\u003e\n\n\u003cp\u003eHospitals and Clinics\u003cbr\u003e\nPharmacies\u003cbr\u003e\nResearch Laboratories\u003cbr\u003e\nOthers\u003cbr\u003e\n \u003cbr\u003e\nBreakup by Region:\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nIndia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nAustralia\u003cbr\u003e\nOthers\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUnited Kingdom\u003cbr\u003e\nItaly\u003cbr\u003e\nSpain\u003cbr\u003e\nRussia\u003cbr\u003e\nOthers\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nOthers\u003cbr\u003e\nMiddle East and Africa\u003cbr\u003e\n \u003cbr\u003e\nCompetitive Landscape:\u003cbr\u003e\nThe competitive landscape of the industry has also been examined with some of the key players being AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A\/S, GlaxoSmithKline Plc., Johnson \u0026amp; Johnson, Merck \u0026amp; Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc.\u003c\/p\u003e\n\n\u003cp\u003eKey Questions Answered in This Report:\u003cbr\u003e\nHow has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years?\u003cbr\u003e\nWhat are the key regional markets?\u003cbr\u003e\nWhat has been the impact of COVID-19 on the global cancer monoclonal antibodies market?\u003cbr\u003e\nWhat is the breakup of the market based on the antibody type?\u003cbr\u003e\nWhat is the breakup of the market based on the medication type?\u003cbr\u003e\nWhat is the breakup of the market based on the application?\u003cbr\u003e\nWhat is the breakup of the market based on the end-user?\u003cbr\u003e\nWhat are the various stages in the value chain of the industry?\u003cbr\u003e\nWhat are the key driving factors and challenges in the industry?\u003cbr\u003e\nWhat is the structure of the global cancer monoclonal antibodies market and who are the key players?\u003cbr\u003e\nWhat is the degree of competition in the industry?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 139 Pages \/ MCW16230681","offer_id":47647150866738,"sku":null,"price":2999.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/cancer-monoclonal-antibodies-market-global-industry-trends-share-size-growth-opportunity-and-forecast-2023-2028","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}